EN DE
Watch TG Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

TG Therapeutics Inc (TGTX) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of TG Therapeutics Inc stock $34.30, price $59.83, that is 42.7% below the price, quality 60 out of 100. Rating: strongly overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

TT TG Therapeutics Inc logo Some data Nov 6, 2026

TG Therapeutics Inc

TGTX · US
Solid, but very expensive

Our calculation puts a fair price 43% below what the stock costs today.

Quality 60/100
Solidly profitable · 55.2% net margin (TTM) · excl. one-off gain FY2025 12.7%
Low debt
Generates free cash flow over the last twelve months
Ranks above peers (8/13)
Revenue last quarter +70% vs. a year ago.
Mixed Growth (revenue 5y +426.7 %/yr in USD)
Wide moat 75/100 · thin data
Insiders sold $274,800 (6M)
Some data
Fair value $34.30 · Strongly overvalued

Risks from the AI analysis

🚩Rivals Roche and Novartis could take BRIUMVI share🚩AI regulatory and IP risks could raise costs🚩Royalties and partner dependence could limit margins
Watch TG Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$61.63 $3.74 Fair Value $34.30 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $3.74 – $61.63 · fair‑value band $18.54 – $59.63 · the $59.83 price screens above the $34.30 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow TG Therapeutics in your weekly email

Every Wednesday you see whether TG Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

Show moreShow less

The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.

Its research pipeline includes various investigational medicines.

The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Stock analysis

TG Therapeutics Inc (TGTX) currently trades at $59.83, while our model-based Fair Value estimate is $34.30, 43% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $69.56 per share, and 3 of the 15 models we run sit above the $59.83 price.

Bear case: the Economic Profit group reads lowest at $12.72, and 12 of the 15 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $18.54 (bear) to $59.63 (bull), the price of $59.83 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

TG Therapeutics Inc reported revenue of $616M in FY2025 versus $6.7M in FY2021, a compound +209.8%/yr. Reported net income was $447M in FY2025.

Key figures

Market cap $9.4B Mid · P/E ratio 21.8 · P/S ratio 11.8 · EPS (TTM) $2.75 · Net margin 55.2% · Return on equity 100% · Return on assets (EBIT) −35.7% (5-year average) · Operating margin 9.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 75 out of 100 (low confidence).

What moves the price

The share trades about 3% below its 52-week high and 122% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −43%, TGTX screens richer than that median.

Fair Value models

Bear $18.54 Fair Value $34.30 Bull $59.63
Price $59.83 · Downside -42.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($2.36 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings $18.54 $34.30 $59.98 74
EPV $4.42 $5.12 $5.71 74
ROIC Compounder $4.52 $6.08 $7.68 72
All 15 models by family
DCF Models
Owner Earnings $18.54 $34.30 $59.98 74
Earnings-Based
Graham-Dodd $19.87 $113.97 $158.49 63
Lynch FV $32.11 $45.87 $59.63 61
PEG = 1.0 $32.11 $45.87 $59.63 57
EPV $4.42 $5.12 $5.71 74
Multiples
P/E Multiple $48.20 $64.27 $80.34 63
P/S Multiple $10.57 $14.09 $17.61 58
P/B Multiple $14.26 $19.01 $23.76 55
EV/EBIT $9.09 $12.51 $15.93 66
EV/EBITDA $7.28 $10.10 $12.92 67
EV/Revenue $6.15 $9.29 $12.43 53
Asset-Based
NCAV (Graham) $0.9300 $1.41 $1.76 55
Economic Profit
Residual Income $12.49 $19.35 $44.34 64
ROIC Compounder $4.52 $6.08 $7.68 72
Growth Earnings
Growth-Adj P/E $48.69 $69.56 $90.42 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 60/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 85
How much profit the company makes from its sales and capital
Quality Growth 72
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 67
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 16
How calm the share price moves, does not count
Price momentum 88
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 97
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $274,800 and none bought.

  • SaleLaurence N CharneyDirector5,000 shares at $54.96$274,800Sep 10, 2026
  • SaleYann EchelardDirector5,000 shares at $32.57$162,850Nov 24, 2025

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 59/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+87.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+504.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+426.7%
Start year 2020 (pandemic). Over 10 years: +129.4% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−179,996.1% (2020) → 20.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: rate outside our plausibility band
not computed

TGTX screens overvalued: fair value 43% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Note from the team Oct 11, 2026
AI conclusion: The established multiple sclerosis franchise with expanding real-world support forms the core strength, while the unproven allogeneic CAR-T pipeline and negative operating cash flow despite high margins mark the main weakness.
Main risk: Competition from Roche's Ocrevus and Novartis' Kesimpta plus emerging BTK inhibitors such as fenebrutinib could reduce BRIUMVI market share or force price concessions and thereby squeeze revenues and margins.
Bull case: Successful differentiation through the subcutaneous formulation, single-dose initiation or the allogeneic CAR-T candidate could expand the addressable market and offset competitive pressure on the core BRIUMVI franchise.
Bear case: If established rivals or new entrants capture greater share in the anti-CD20 segment while royalties and compliance costs remain elevated, the company could face sustained margin pressure and slower revenue growth from its primary product.
TG Therapeutics is set to present seven-year BRIUMVI outcomes alongside initial Phase 1 results for its allogeneic CAR T candidate in primary progressive multiple sclerosis at MSToronto2026 later this month. The established multiple sclerosis franchise shows expanding real-world support while the off-the-shelf cell therapy remains early and unproven in a harder-to-treat setting. Will the core product keep extending its reach or will pipeline execution determine the longer-term path?
Join the discussion →

Compare TG Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 60 · Top 25%
Fair Value upside −42.7% · Above median
Profitability
Return on equity (12 months) 100.3% · Top 25%
Return on assets 42.1% · Top 25%
Net margin (12 months) 55.2% · Top 25%
Operating margin (12 months) 9.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 70.3% · Top 25%
Balance sheet
Debt / equity 0.38× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 21.8× · Cheaper than median
P/B 14.52× · Priciest 25%
P/S (12 months) 11.77× · Pricier than median
EV/EBITDA 70.2× · Priciest 25%
PEG 1.61× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)100 · sector 0
HEALTH (low debt)81 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs TGTX
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs TGTX
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs TGTX
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs TGTX
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs TGTX
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs TGTX
argenx SE ARGX $927.21 $908.40 −2% vs TGTX
CSL Limited CSL A$200.77 A$183.04 −9% vs TGTX
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs TGTX
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs TGTX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

TG Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "TG Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/TGTX

Frequently asked questions

Is TG Therapeutics Inc (TGTX) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $34.30 versus a price of $59.83, about 43% lower (overvalued).
What is the fair value of TGTX?
Our model-based fair value for TG Therapeutics Inc is $34.30 (as of Nov 6, 2026), built from audited fundamentals. The current price: $59.83.
What is the quality score of TGTX?
TG Therapeutics Inc has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TG Therapeutics Inc (TGTX)?
Our model-based price target is the fair value of $34.30 (as of Nov 6, 2026) from 15 valuation models. Cautious scenario $18.54, optimistic scenario $59.63. It is a calculation from audited fundamentals, not an analyst target.
What is the TG Therapeutics Inc stock forecast for 2026?
Our models put fair value at $34.30, about 43% lower versus a price of $59.83 (overvalued). Cautious scenario $18.54, optimistic scenario $59.63. The calculation is refreshed regularly with new filings.
What is the revenue of TG Therapeutics Inc (TGTX)?
TG Therapeutics Inc reported trailing-twelve-month revenue of about $800M (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of TG Therapeutics Inc (TGTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TG Therapeutics Inc it is $34.30 per share (as of Nov 6, 2026), against a price of $59.83. It is the blended result of 15 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is TG Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, TGTX trades above its calculated fair value: price $59.83, fair value $34.30, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TGTX?
No. The price is what the market pays today ($59.83); the fair value is what the company's own numbers justify ($34.30). For TG Therapeutics Inc the two are $25.53 per share apart. That gap is exactly why we show both numbers side by side.
How much is TG Therapeutics Inc worth?
The market values TG Therapeutics Inc at about $9.4B (market capitalisation, as of Nov 6, 2026). Per share that is $59.83; our models calculate a fair value of $34.30 per share.
What do the bullish and bearish scenarios say about TGTX?
Our models span a range for TG Therapeutics Inc: cautious scenario $18.54, base $34.30, optimistic $59.63 per share (as of Nov 6, 2026, price $59.83). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TGTX?
TG Therapeutics Inc trades at a price-to-earnings ratio of 21.8 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $34.30 is built from several models across several years. Other multiples: PEG 1.6, P/B 14.5, P/S 11.8, EV/EBITDA 70.2.
What is the PEG ratio of TGTX?
The PEG ratio of TG Therapeutics Inc is 1.61 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of TG Therapeutics Inc (TGTX)?
Balance-sheet figures for TG Therapeutics Inc (as of Nov 6, 2026): return on equity 100.3%, debt of 0.38 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is TGTX from its 52-week high?
TG Therapeutics Inc trades at $59.83, about 3% below its 52-week high of $61.63 and 122% above the low of $26.94 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $34.30 is for.
Which stocks are comparable to TG Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TG Therapeutics Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $59.83, calculated fair value $34.30 (−43%), Quality Score 60/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TGTX calculated?
We run TG Therapeutics Inc through 15 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $34.30 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. TG Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TG Therapeutics Inc (TGTX)?
The closing price on Nov 6, 2026 was $59.83. Our model-based fair value is $34.30, about 43% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TG Therapeutics Inc right now?
The model range is unusually wide ($18.54 to $59.63). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of TG Therapeutics Inc

How large is the market capitalisation of TG Therapeutics Inc (TGTX)?
The market capitalisation of TG Therapeutics Inc is $9.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of TG Therapeutics Inc (TGTX)?
The price-to-sales ratio of TG Therapeutics Inc is 11.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of TG Therapeutics Inc (TGTX)?
Earnings per share at TG Therapeutics Inc are $2.75 (price ÷ EPS = P/E 21.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of TG Therapeutics Inc (TGTX)?
The net margin of TG Therapeutics Inc is 55.2% (last twelve months), excl. one-off gain FY2025 12.7%. How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of TG Therapeutics Inc (TGTX)?
The return on equity (ROE) of TG Therapeutics Inc is 100% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TG Therapeutics Inc (TGTX)?
On an EBIT basis the return on assets of TG Therapeutics Inc is −35.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of TG Therapeutics Inc (TGTX)?
The operating margin of TG Therapeutics Inc is 9.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at TG Therapeutics Inc (TGTX)?
Revenue at TG Therapeutics Inc is growing +70.3% versus a year earlier (3y avg +505%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at TG Therapeutics Inc (TGTX)?
Earnings per share at TG Therapeutics Inc are growing −70.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does TG Therapeutics Inc (TGTX) generate?
The free cash flow of TG Therapeutics Inc is −$25.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does TG Therapeutics Inc (TGTX) carry?
The net debt of TG Therapeutics Inc is $182M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch TG Therapeutics Inc in the live analysis

One click puts TG Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.